Temozolomide based treatment in glioblastoma: 6 vs. 12 months-Reference-Cited by-同舟云学术

Temozolomide based treatment in glioblastoma: 6 vs. 12 months

Published:2024-07-02 Issue:3 Volume:28 Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Fasano Morena¹,Pirozzi Mario¹,De Falco Vincenzo²,Miceli Chiara¹,Farese Stefano¹,Zotta Alessia¹,Famiglietti Vincenzo¹,Vitale Pasquale²,Giovanni Ilaria Di²,Brancati Christian²,Carfora Vincenzo³,Solari Domenico⁴,Somma Teresa⁴,Cavallo Luigi⁴,Cappabianca Paolo⁴,Conson Manuel⁵,Pacelli Roberto⁵,Ciardiello Fortunato¹,Addeo Raffaele²

Affiliation:

1. Medical Oncology Unit, Department of Precision Medicine, University of Campania Luigi Vanvitelli, I‑80131 Naples, Italy

2. Oncology Unit, ‘San Giovanni di Dio’ Hospital, ASL Napoli 2 Nord, I‑80020 Frattamaggiore, Italy

3. Radiation Oncology Unit, Department of Radiation Oncology, ‘San Pio’ Hospital, I‑82100 Benevento, Italy

4. Division of Neurosurgery, Department of Neurosciences, Reproductive and Odontostomatological Sciences, I‑80131 Naples, Italy

5. Department of Advanced Biomedical Sciences, University of Naples Federico II, I‑80131 Naples, Italy

Publisher

Spandidos Publications

Reference54 articles.

1. Epidemiology of glial and non-glial brain tumours in Europe;Crocetti;Eur J Cancer,2012

2. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016;Ostrom;Neuro Oncol,2019

3. Glioblastoma incidence rate trends in Canada and the United States compared with England, 1995–2015;Davis;Neuro Oncol,2020

4. Brain tumours: Rise in glioblastoma multiforme incidence in England 1995–2015 suggests an adverse environmental or lifestyle factor;Philips;J Environ Public Health,2018

5. Human glioblastoma arises from subventricular zone cells with low-level driver mutations;Lee;Nature,2018